US 12,251,431 B2
Botulinum toxin for use in treatment of autism spectrum disorders
Roland M. Williams, Beaumont, TX (US)
Assigned to Penland Foundation, Beaumont, TX (US)
Filed by Penland Foundation, Beaumont, TX (US)
Filed on Aug. 4, 2022, as Appl. No. 17/880,962.
Application 17/880,962 is a continuation of application No. 17/525,367, filed on Nov. 12, 2021, granted, now 11,439,694.
Application 17/525,367 is a continuation of application No. PCT/US2020/056206, filed on Oct. 17, 2020.
Application PCT/US2020/056206 is a continuation of application No. 16/657,933, filed on Oct. 18, 2019, granted, now 10,722,552, issued on Jul. 28, 2020.
Application PCT/US2020/056206 is a continuation of application No. 16/657,950, filed on Oct. 18, 2019, abandoned.
Prior Publication US 2022/0378885 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/48 (2006.01); A61P 25/00 (2006.01); C12N 9/52 (2006.01)
CPC A61K 38/4893 (2013.01) [A61P 25/00 (2018.01); C12N 9/52 (2013.01); C12Y 304/24069 (2013.01)] 18 Claims
 
1. A method of treating autism spectrum disorder (ASD) in a patient in need thereof, comprising administering a botulinum toxin to the patient, thereby treating ASD wherein the patient is administered by subcutaneous or intradermal injection, 1-4 units to and/or around the vicinity of a trigeminal nerve, 1-4 units to and/or around the vicinity of a cervical nerve, lateral to the patient's spine, 1-4 units to and/or around the vicinity of a thoracic nerve, lateral to the spine, 1-4 units to and/or around the vicinity of a lumbar nerve, lateral to the spine, and/or 1-4 units to and/or around the vicinity of a sacral nerve, lateral to the spine, wherein a total dosage of the botulinum toxin is less than or equal to about 150 units.